Efficacy and safety of combination of ulinastatin and meglumine cyclic adenosine monophosphate in the treatment of acute myocardial infarction, and its effect on serum levels of hs-CRP, cTnI and CK

Purpose: To determine the efficacy and safety of a combination ulinastatin meglumine cyclic adenosine monophosphate (cAMP) in treatment acute myocardial infarction (AMI), its effect on serum levels hypersensitive-c-reactive protein (hs-CRP), cardiac troponin I (cTnI), creatine kinase (CK).Methods: A total 90 AMI patients admitted to The Second Affiliated Hospital Qiqihar Medical College, City, Heilongjiang Province, China from January 2019 2020 were selected randomized (in 1:1 ration) into control group study group. Patients two groups received cAMP, while those were, addition, treated with ulinastatin. compared regard clinical efficacy, function indices, biochemical incidence drug-related side effects, duration number episodes angina pectoris, neuroendocrine hormones.Results: exhibited remarkably higher effectiveness indices (p < 0.05). However, lower drug toxicity, smaller shorter panel reactive antibodies (PRA) observed when (p< 0.001).Conclusion: Treatment cAMP significantly reduces symptoms patients, remarkable high safety. Furthermore, it down-regulates hs-CRP, cTnI CK. Thus, seems superior conventional therapy.